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  15 
ABSTRACT 16 
Aims - We previously demonstrated that solid drug nanoparticles (SDNs) lopinavir dispersed into 17 
aqueous media display favourable pharmacokinetics.  18 
Methods - The impact of lopinavir SDNs on the function and phenotype of primary human T cells and 19 
macrophages (primary sites of HIV replication), was investigated. 20 
Results - Lopinavir significantly increased IL- ?ɴ  ? ?-fold higher than untreated cells; P=0.045) and 21 
TNFɲ (6-fold higher than untreated cells; P=0.018) secretion from monocyte-derived macrophages, 22 
whereas lopinavir SDNs did not elicit these responses at comparable drug concentrations. Lopinavir 23 
SDNs were demonstrated to be immunologically inert to human T cells and monocyte-derived 24 
macrophages.  25 
Conclusion  W The lopinavir SDN was demonstrated to exhibit comparable, or favourable behaviour 26 
compared to a lopinavir aqueous solution in the employed biocompatibility assessments. 27 
 28 
  29 
INTRODUCTION 30 
Antiretroviral therapy has significantly improved the morbidity and mortality associated with HIV 31 
infection, but an estimated 20-30% of patients initiating therapy still discontinue treatment within 32 
two years, the majority being toxicity related but also a significant number due to virological failure 33 
[1]. Toxicity and drug failure are costly as toxicity results in significant morbidity and subsequent 34 
regimens are associated with higher pill burden and a higher expensive to healthcare providers. The 35 
introduction of HIV protease inhibitors (PIs) in the 1990s, significantly reduced morbidity and 36 
mortality and prolonged the lifespan of patients [2]. However, there are a number of side effects 37 
associated with these drugs such as; dyslipidaemia, insulin resistance, lipodystrophy and 38 
hepatotoxicity [2-5]. Although the underlying mechanisms of these side effects is yet to be fully 39 
elucidated, a number of possibilities have been demonstrated such as; induction of IL-6 and TNFɲ 40 
secretion [6], activation of the unfolded protein response [7], impairment of protein synthesis and 41 
activation of AMP-activated protein kinase (AMPK) [8]. PIs also exhibit incomplete absorption and 42 
rapid systemic clearance, resulting in a requirement for pharmacoenhancement by co-43 
administration of ritonavir or cobicistat as a pŚĂƌŵĂĐŽŬŝŶĞƚŝĐ  “ďŽŽƐƚĞƌ ? ? ĞƐƉŝƚĞ44 
pharmacoenhancement, pharmacokinetics are highly variable within populations and the class has 45 
attracted interest by many investigators exploring nanotechnology-enabled drug delivery [9-11]. 46 
 47 
Many nanomaterials platforms are being investigated for their potential to augment drug delivery. 48 
Unlike nanocarrier systems (e.g. lipid-based, polymer-based or inorganic materials), solid drug 49 
nanoparticles (SDNs) rely upon advanced formulation tools to generate nanoparticles that are 50 
composed of the drug itself. To date, the most commercially successful SDN manufacturing platform 51 
has been provided by nanomilling technologies [12]. The overwhelming majority of SDN 52 
formulations have been developed for oral dosing and are thought to release drug prior to 53 
absorption such that particulates do not enter the systemic circulation. However, recent work has 54 
illustrated that intact particles are able to traverse intestinal monolayers [13]. Moreover, recent 55 
success of parenterally administered SDNs as long-acting depot formulations [14, 15], along with 56 
recent work exploring intravenous delivery of SDNs [16], has resulted in the need for a more robust 57 
understanding of their safety. Therefore, the current work focused on assessing the putative 58 
immunological consequences of direct SDN exposure.   59 
 60 
Lopinavir SDNs were produced using a previously reported emulsion-templated freeze-drying (ETFD) 61 
technique [17] and were shown to exhibit similar pharmacokinetics to a conventional preclinical 62 
preparation of lopinavir in a rodent model [18]. In HIV therapy, delivery of antiretrovirals to T cells 63 
and macrophages is vital since these are the primary sites of HIV replication in vivo [19]. However, a 64 
prerequisite for this as a valid strategy depends upon the absence of unwanted immunogenic or 65 
immunosuppressive effects such as those described for other nanoparticle materials [20-22]. The 66 
purpose of this work was to assess the impact of lopinavir aqueous solution and lopinavir SDNs on 67 
the function of human T cells and macrophages ex vivo.  68 
 69 
 70 
  71 
MATERIALS AND METHODS 72 
Preparation and physical analysis of lopinavir SDNs  73 
 Samples are prepared using a 70 mgmL
-1
 stock solution of Lopinavir (LPV) in chloroform, a 22.5 74 
mgmL
-1
 of poly(vinyl alcohol) (MW = 9500 g/mol, PVA) in water and a 22.5 mgmL
-1
 stock solution of 75 
ɲ-tocopherol polyethylene glycol succinate (TPGS) in water. Stock solutions are added in the 76 
following proportion; 100 µl LPV; 90 µl PVA, 45 µl TPGS and 265 µl of water, therefore solid mass is 77 
10 mg with the ratio; 70% LPV, 20% PVA and 10% TPGS in a 1:4 oil to water (O/W) mix. The mixtures 78 
are the emulsified using a Covaris S2x for 30 seconds with a duty cycle of 20, an intensity of 10 and 79 
500 cycles/burst in frequency sweeping mode. After which, the samples were immediately 80 
cryogenically frozen and lyophilized using a Virtis benchtop K freeze-drier for 48hrs to produce off 81 
white dry porous monolith products. Samples were then sealed in individual vials until analysis. The 82 
amorphous nature of the solid monoliths were confirmed via Powder x-ray diffraction (PXRD) using a 83 
WĂŶĂůǇƚŝĐĂůy ?WĞƌƚWZKDWŝŶƐƚƌƵŵĞŶƚǁŝƚŚy ?WĞƌƚKƉĞƌĂƚŽƌ/ŶƚĞƌĨĂĐĞ ?ǀĞƌƐŝŽŶ ? ? ?ď )ƐŽĨƚǁĂƌĞ ?dŚĞ84 
instrument was equipped with a high throughput screening (HTS) XYZ stage, X-ray focusing mirror 85 
and PIXcel detector, using Ni-fiůƚĞƌĞĚƵ<ɲƌĂĚŝĂƚŝŽŶ ?ĂƚĂǁĞƌĞŵĞĂƐƵƌĞĚŽǀĞƌƚŚĞƌĂŶŐĞ ? W50 ° in 86 
у ? ? ? ? ? ?ƐƚĞƉƐŽǀĞƌ ? ?ŵŝŶŝŶƚƌĂŶƐŵŝƐƐŝŽŶŵŽĚĞǁŝƚŚƚŚĞƐŽůŝĚŵŽŶŽůŝƚŚƐĂŵƉůĞƐŚĞůĚŽŶƚŚŝŶDǇůĂƌ87 
film in aluminum well plates. LPV SDN samples were shown to be amorphous with no crystallinity 88 
present. In order to determine the dispersed SDN particle characteristics, samples were dispersed by 89 
addition of 3.5 mL of water (therefore 1 mgmL
-1
 with respect to LPV content). Z-average diameter 90 
(Dz ) ? ĞƚĂ ƉŽƚĞŶƚŝĂů  ?ɺ ) ĂŶĚ ƉŽůǇĚŝƐƉĞƌƐŝƚǇ ŝŶĚĞǆ(PdI) were determined by dynamic light scattering 91 
 ?>^ )ĂƚĂƚĞŵƉĞƌĂƚƵƌĞŽĨ ? ?ȗƵƐŝŶŐĂDĂůǀĞƌŶĞƚĂƐŝǌĞƌEĂŶŽ^ĞƋƵŝƉƉĞĚǁŝƚŚĂ ?ŵt,Ğ-Ne, 633 92 
nm laser and using plastic disposable cuvettes. Malvern Zetasizer software version 6.20 was used for 93 
data anaůǇƐŝƐ ?ɺŵĞĂƐƵƌĞŵĞŶƚƐǁĞƌĞĂůƐŽĐĂƌƌŝĞĚŽƵƚĂƚ ?ŵŐŵ>-1 ? ? ?ȗ ?ĂŶĚĂŶŝŶŝƚŝĂůƉ,ŽĨ ? ? ? ?ƵƐŝŶŐ94 
disposable capillary zeta cells. Dz ?ɺĂŶĚƉŽůǇĚŝƐƉĞƌƐŝƚǇŵĞĂƐƵƌĞŵĞŶƚƐǁĞƌĞŽďƚĂŝŶĞĚĂƐĂŶĂǀĞƌĂŐĞŽĨ95 
3 individual measurements and were obtained using the instrƵŵĞŶƚ ?Ɛ ĂƵƚŽŵĂƚŝĐ ŽƉƚŝŵŝƐĂƚŝŽŶ96 
settings.  97 
Detection of endotoxin using ELISA-based assays 98 
Endotoxin was measured in lopinavir aqueous stock solutions (0.5% DMSO) and lopinavir SDN 99 
preparations using the ENDOlisa kit (Cambridge Biosciences, UK). Briefly, reagents were resuspended 100 
as instructed by the manufacturer and a serial dilution of prepared lipopolysaccharide (LPS, 101 
Invivogen, UK) was made, ranging from 0.005-500 EU/mL. Samples were diluted 1:5 in endotoxin 102 
free water and a spiked sample was prepared as a control for interference with the assay by the drug 103 
or nanoparticles. Samples were added to wells, followed by binding buffer, and plates were then 104 
protected from light and incubated at 37°C for 90 minutes with continual shaking. Wells were then 105 
washed twice with wash buffer prior to addition of assay reagent. Immediately following addition of 106 
assay reagent a zero-time point was recorded on the plate reader. Plates were then incubated at 107 
37°C for a further 90 minutes and read again. Data were corrected for the zero-time point and a 4-108 
point logistic curve was used to interpolate unknown concentrations. 109 
Isolation of peripheral blood mononuclear cells from peripheral blood samples 110 
Healthy volunteer blood was collected via venepuncture under ethics approval from the University 111 
Physical Interventions sub-committee (Reference RETH000563). Informed consent was given and 112 
accepted by the healthy volunteers for use of whole blood in subsequent assays. Peripheral Blood 113 
Mononuclear Cells (PBMC) were isolated as described previously [22]. Blood was layered over Ficoll 114 
and centrifuged at 800xg for 30 minutes (4°C). The PBMC interface was then transferred to a fresh 115 
universal tube prior to three washes in phosphate buffered saline solution (PBS). PBMC were then 116 
counted using a Nucleocounter and cell densities adjusted to the required number for subsequent 117 
experiments, as described in relevant sections below. 118 
Lymphocyte activation via CD2/CD3/CD28 conjugated MACSiBead particles 119 
MACSiBead particles (Miltenyi Biotec, UK) were prepared following the manufacturers guidelines. 120 
MACSiBead particles (2.5 x 10
6
) were added to a sterile universal tube with complete culture media 121 
(RPMI-1640, 10% FCS). MACSiBead particles were then centrifuged (450xg) for 5 minutes, the 122 
supernatant fraction was removed and the MACSiBeads were resuspended in complete culture 123 
media (RPMI-1640, 10% FCS). PBMC densities were adjusted to 5 x 10
6
 cells per mL. PBMC and 124 
MACSiBeads preparations were then combined and incubated in a humidified incubator, at 37°C for 125 
24 hours. In addition to untreated controls and MACSiBead positive controls, PBMC were treated 126 
with lopinavir aqueous solution (10µM) or lopinavir SDNs (10µM) to assess potential for lymphocyte 127 
activation. Additionally, PBMC were co-cultured with MACSiBead particles and lopinavir aqueous 128 
solution (10µM) or lopinavir SDNs (10µM) to assess potential inhibition or enhancement of 129 
activation via CD2/CD3/CD28. Finally, PBMC were cultured with only lopinavir (10µM) or lopinavir 130 
SDNs (10µM) for 24 hours prior to activation with MACSiBead particles, to assess direct effects on 131 
the system. 132 
Preparation and activation of primary monocyte-derived macrophage (MDM) from healthy 133 
volunteers.  134 
CD14+ positive cells were isolated from crude PBMC preparations via magnetic bead based cell 135 
separation (MACS beads, Miltenyi Biotec, UK) ? ? ?нĐĞůůƐǁĞƌĞƚŚĞŶĐƵůƚƵƌĞĚĨŽƌ ? ?ĚĂǇƐŝŶ/ƐĐŽǀĞ ?Ɛ136 
DŽĚŝĨŝĞĚƵůďĞĐĐŽ ?ƐŵĞĚŝƵŵ(Sigma, UK) containing human serum (20%) and Macrophage colony 137 
stimulating factor (M-CSF, 10ng/mL, Miltenyi Biotec, UK). Following differentiation into MDM, cells 138 
were incubated in the presence of lipopolysaccharide (LPS, 1µg/mL), conventional lopinavir (10µM) 139 
or lopinavir SDNs (10µM) for 24 hours. Cell culture supernatant fractions were then harvested for 140 
cytokine analysis. 141 
Measurement of cytokine concentrations in activated PBMC and MDM cultures 142 
Aliquots of culture supernatant fractions (100µL) were taken for analysis of cytokine secretion 143 
following 24-hour incubation. Cytokine concentrations were measured via multiplex cytokine assays 144 
conducted using the Bioplex 200 system (Biorad, UK). IL-2, IL- ? ?ĂŶĚ/&EɶǁĞƌĞŵĞĂƐƵƌĞĚĨŽƌWD145 
stimulation and IL- ?ɴ ? />-6, IL- ? ĂŶĚ dE&ɲ ǁĞƌĞ ŵĞĂƐƵƌĞĚ ĨŽƌ DD ƐƚŝŵƵůĂƚŝŽŶ ? ƌŝĞĨůǇ ? ĐŽƵƉůĞĚ146 
beads (50µL) were added to every well on a 96 well plate. Plates were prĞƉĂƌĞĚƉĞƌŵĂŶƵĨĂĐƚƵƌĞƌ ?Ɛ147 
instructions. Cell culture supernatants were added to the plate alongside multiplexed standard 148 
curves for the measured cytokines. Incubations were carried out at room temperature, on a plate 149 
shaker. Detection antibodies were added for 30 minutes following three washes. Plates were again 150 
washed three times prior to the addition of streptavadin-PE antibodies (50µL) and incubation on a 151 
plate shaker for 10 minutes. Plates were then washed for a final three times and assay buffer 152 
(125µL) added to each well. Plates were then analysed on a Bioplex 200 analyser using the 153 
recommended gating settings. 154 
Flow cytometric measurement of activation markers in CD4+ and CD8+ T cells 155 
Prior to analysis of activation marker expression by flow cytometry, MACSiBeads were removed 156 
from cell cultures ƉĞƌŵĂŶƵĨĂĐƚƵƌĞƌ ?Ɛ ŝŶƐƚƌƵĐƚŝŽŶƐƵƐŝŶŐŵĂŐŶĞƚŝĐ ƐĞƉĂƌĂƚŝŽŶ ? PBMC samples were 157 
then stained with either CD4-FITC or CD8-FITC conjugated antibodies (1:11, Miltenyi Biotec, UK) in 158 
buffer for 30 minutes prior to washing three times (800xg, 5 minutes) in ice cold Phosphate Buffered 159 
Saline (PBS) to enable gating of CD4+ and CD8+ T cells along with a combination of antibodies 160 
(Miltenyi Biotec, UK) against either CD25-PE, CD44-APC, CD69-APC or CD95-APC. Samples were then 161 
washed three times (800xg, 5 minutes) in ice cold Phosphate Buffered Saline (PBS) before analysis 162 
on a BD FACS CantoII flow cytometer. The PBMC population was gated using linear forward and side 163 
scatter. 164 
Leukocyte proliferation, in response to nanoparticles, measured by incorporation of 
3
H-thymidine 165 
PBMC number was adjusted to 2.5 x 10
6
 cells per ml and 25,000 cells per well were added to a 96 166 
well round bottomed plate. Phytohaemagglutinin (PHA, Sigma, UK) (20µg/mL) was then added to 167 
each well followed by the addition of either medium or medium containing drug (lopinavir or 168 
lopinavir SDNs, 10µM) taking into account the resultant dilution. Plates were then cultured for 48 169 
hours (37°C; 5% CO2 in air), the final 16 h with 1µCi [
3
H]-thymidine (Moravek, USA) per well. Cells 170 
were then harvested onto a filtermat using a tomtec harvester 96 and sealed in a sample bag with 171 
melt on scintillation cocktail. Incorporated radioactivity was counted on a Perkin-Elmer MicroBeta 172 
detector. 173 
Impact of nanoparticles on phagocytosis in primary, human, monocyte-derived macrophages  174 
CD14+ cells were isolated from PBMC samples by magnetic bead separation and incubated in 175 
/ƐĐŽǀĞ ?ƐDŽĚŝĨŝĞĚƵůďĞĐĐŽƐ ? DĞĚŝĂ (IMDM) containing macrophage colony stimulating factor (M-176 
CSF) (10ng/mL) for 12 days replacing the media every three days to differentiate into monocyte-177 
derived macrophages (MDM). Following differentiation, MDM were treated with lopinavir or the 178 
lopinavir SDNs (10µM) for 24 hours. After the incubation period, phagocytic activity was assessed 179 
using pHrodo reagent (Molecular probes, UK). MDM were plated at 100,000 cells per well in a black 180 
walled plate ? Ɖ,ƌŽĚŽ ? ŝŽWĂƌƚŝĐůĞƐ ? ǁĞƌĞ ƉƌĞƉĂƌĞĚ ďǇsuspending 2 mg of lyophilized product in 181 
2mL of uptake buffer (Hanks Balanced Salt Solution [HBSS], 20 mM HEPES, pH 7.4) and briefly 182 
vortexed to completely suspend the particles. The positive control for inhibition of phagocytosis was 183 
Cytochalasin B (10µM, Sigma, UK)). Culture media was aspirated from each well and replaced with 184 
the pHrodo bioparticle solution. The plate was covered and transferred to an incubator at 37°C 185 
without CO2 to prevent artificial acidification of the uptake buffer thereby minimising background 186 
signal. Plates were read using a plate reader with an excitation of 550nm and emission of 600nm. 187 
Statistical analysis 188 
Distribution of the data was assessed using a Shapiro-Wilk test. For comparisons between datasets 189 
either an unpaired t-test or a Mann-Whitney test was used for normally and non-normally 190 
distributed data respectively. Stats Direct software (version 3.0.171) was used for data analysis and a 191 
P value < 0.05 was considered statistically significant.  192 
RESULTS 193 
Physical characteristics of lopinavir solid drug nanoparticles  194 
3.5 mL of deionised water was added to the LPV ETFD monolith, thus creating 1 mgmL
-1
 SDN 195 
dispersion with respect to LPV content. Hydrodynamic diameter (Z-average Dz), PdI and zeta 196 
potential were assessed using dynamic light scattering (DLS) (representative DLS traces can be seen 197 
in supplementary information figure 1). Dz was recorded as 566 ± 26 nm, PdI at 0.37 ± 0.02 and ɺ at -198 
12 ± 2 mV. Lopinavir SDN were stable at a range of pH and over an extended period of time 199 
(supplementary information figure 2 & 3 respectively) 200 
Quantification of endotoxin in lopinavir and lopinavir nanoparticle preparations 201 
The presence of endotoxin in drug and nanoparticle samples was assessed using ELISA-based 202 
techniques. Following interpolation form a standard curve the level of endotoxin in the lopinavir 203 
solution and lopinavir SDN samples was 0.008 EU/mL and 0.063 EU/mL, respectively. In order to 204 
ensure nanoparticles did not interfere with the assay, samples of lopinavir and lopinavir SDNs were 205 
also spiked with 5 EU/mL of endotoxin. Recovery of endotoxin was 5.32 EU/mL and 6.13 EU/mL for 206 
the lopinavir and lopinavir sold drug nanoparticles, respectively. 207 
Impact of lopinavir and lopinavir solid drug nanoparticles on T Cell cytokine secretion 208 
Anti-CD2, CD3 and CD28 beads were used to stimulate T cells in the PBMC population. Secretion of 209 
IL-2 (figure 1a) from PBMC treated with beads was significantly higher than that of untreated cells 210 
(148 fold higher; P=0.0079). Treatment of PBMC with lopinavir or lopinavir SDNs resulted in 65% and 211 
74% lower secretion of IL-2, respectively, although this was not statistically significant (P=0.095 & 212 
P=0.071, respectively). Coincubation of PBMC with beads and either lopinavir or lopinavir SDN did 213 
not result in significantly different secretion of IL-2 compared to bead treated cells (P=0.54 & P=0.69, 214 
respectively). PBMC were also treated with either lopinavir of lopinavir SDNs for 24 hours prior to 215 
stimulation with beads. Preincubation with lopinavir (3-fold greater; P=0.016) or lopinavir SDN (4-216 
fold greater; P=0.0079) significantly increased bead stimulated IL-2 secretion. However, there were 217 
no differences in the stimulation between cells pre-treated with lopinavir or lopinavir SDN for 24 218 
hours (P=0.42). 219 
Bead treatment similarly increased IL-10 secretion (figure 1b) compared to unstimulated cells (58-220 
fold increase; P=0.0079). When compared to unstimulated controls, cells incubated with lopinavir or 221 
lopinavir SDNs did not secrete significantly different concentrations of IL-10 (P=0.31 & P=0.84, 222 
respectively). Additionally, coincubation of cells with beads and either lopinavir or lopinavir SDNs did 223 
not result in significantly different concentrations of IL-10 compared to bead stimulated cells (P=0.15 224 
& P=0.42 respectively). Pre-treatment of PBMC with lopinavir SDNs for 24 hours prior to stimulation 225 
with beads did not result in significantly different IL-10 secretion compared to bead stimulated cells 226 
(P=0.84). However, there was a trend towards lower IL-10 secretion from cells pre-treated with 227 
lopinavir for 24 hours prior to bead stimulation (54% lower: P=0.056). No significant differences 228 
were observed between lopinavir and lopinavir SDN treatments for any of the experimental 229 
conditions (P>0.1 for each). 230 
Bead treatment also resulted in significantly higher IFNɶ secretion (figure 1c) from PBMC than 231 
unstimulated cells (41-fold higher; P=0.0079). Treatment with both lopinavir and lopinavir SDNs 232 
resulted in a decrease in IFNɶ concentrations below the limit of detection (6.4pg/mL). No significant 233 
difference was observed between bead stimulated PBMC and those stimulated with beads and co-234 
incubated with lopinavir (P=0.42) or lopinavir SDNs (P=0.84). Similarly, no significant difference was 235 
observed for cells pre-treated with lopinavir (P=0.22) or lopinavir SDNs (P=0.31) for 24 hours prior to 236 
stimulation with beads. 237 
 238 
Figure 1. Analysis of cytokine secretion from peripheral blood mononuclear cells treated with 239 
lopinavir or lopinavir solid drug nanoparticles. Concentrations of IL-2 (a), IL-10 (b) and IFNɶ (c) were 240 
measured in culture supernatant 24 hours post incubation with lopinavir or lopinavir SDNs. Anti-241 
CD2, CD3 and CD28 beads were used as a positive control. Data presented as mean ± SD, N=6. 242 
 243 
Impact of lopinavir and lopinavir nanoparticles on T lymphocyte activation markers 244 
Expression of classic markers of activation were determined in CD4+ and CD8+ T cells (figure 2a & 245 
2b, respectively). In CD4+ T cells (figure 2a) stimulation with beads resulted in a significantly higher 246 
expression of CD44 (1.3-fold higher; P=0.0159) and CD69 (10-fold higher; P=0.0079). CD25 (2.2-fold 247 
higher) and CD95 (1.15-fold higher) expression was higher in bead treated cells but the differences 248 
were not statistically significant. Similarly, in CD8+ T cells (figure 2b) bead stimulation resulted in 249 
significantly higher expression of CD25 (2.9-fold higher; P=0.045), CD44 (1.3-fold higher; P=0.035) 250 
and CD69 (4.6-fold higher; P=0.032) but not CD95 (1.9-fold higher; P=0.055). There was no 251 
significant difference in expression of activation markers when cells were treated with lopinavir or 252 
lopinavir SDNs. Similarly, lopinavir and lopinavir SDNs did not significantly affect stimulation of cells 253 
with beads.  254 
 255 
Figure 2. Analysis of markers of activation in CD4+ and CD8+ T cells treated with lopinavir or 256 
lopinavir solid drug nanoparticles. Levels of expression of CD25, CD44, CD69 and CD95 were 257 
determined by multiparameter flow cytometry in CD4+ (a) and CD8+ (b) T cells from PBMC 24 hours 258 
post incubation with lopinavir or lopinavir SDNs. Anti-CD2, CD3 and CD28 beads were used as a 259 
positive control. Data presented as mean ± SD, N=6. When compared to unstimulated cells 260 
*=P<0.05. 261 
  262 
Impact of lopinavir and lopinavir solid drug nanoparticles on lymphocyte proliferation 263 
To determine the impact on lymphocyte proliferation and the response of lopinavir and lopinavir 264 
SDN treated PBMC to known mitogens, incorporation of 
3
H-thymidine was used as a marker of 265 
cellular proliferation. Treatment with PHA resulted in a 51-fold higher proliferation of cells (P=0.02) 266 
than that of unstimulated PBMC (figure 3). Lopinavir (P=0.46) and lopinavir SDNs (p=0.27) did not 267 
result in any significant effect upon proliferation compared to unstimulated cells and there was no 268 
difference between lopinavir and lopinavir SDN treated cells (P=0.12). Similarly, co-incubation of 269 
PBMC with lopinavir or lopinavir SDNs and PHA did not impact the proliferative response compared 270 
to PHA only treated cells (P=0.91 and P=0.61, respectively). Finally, there was no difference observed 271 
between cells co-incubated with PHA and lopinavir and that of PHA and lopinavir SDNs (P0.48). 272 
 273 
Figure 3. Analysis of proliferation of PBMC in response to treatment lopinavir or lopinavir solid 274 
drug nanoparticles in the absence and presence of PHA. Measurement of incorporated 
3
H-275 
thymidine was determined by liquid scintillation counting in PBMC 24 hours post incubation with 276 
lopinavir or lopinavir SDNs. PHA was used as a positive control. Data presented as mean ± SD, N=6.  277 
Impact of lopinavir and lopinavir nanoparticles on secretion of cytokines from Monocyte-Derived 278 
Macrophages 279 
MDM were generated from primary human monocytes and treated with either lopinavir or lopinavir 280 
SDNs for 24 hours (figure 4). Lipopolysaccharide (LPS) was used as a positive control for stimulation 281 
of macrophages. Treatment with LPS resulted in a 32-fold higher secretion of IL- ?ɴ ?Wс ? ? ? ? ? ) ?1360-282 
fold higher secretion of IL-6 (P=0.0079), 158-fold higher secretion of IL-8 (P=0.0079) and a 458-fold 283 
higher secretion of TNFɲ (P=0.0066). Aqueous lopinavir treatment resulted in a significantly higher 284 
secretion of IL-1ɴ  ?9-fold higher; P=0.045) and TNFɲ (6-fold higher; P=0.018) than untreated cells, 285 
whereas treatment of MDM with lopinavir SDNs did not result in significantly different cytokine 286 
secretion compared to controls. 287 
 288 
Figure 4. Analysis of cytokine secretion from monocyte derived macrophages treated with 289 
lopinavir or lopinavir solid drug nanoparticles. Concentration of cytokines in cell culture milieu 24 290 
hours post treatment with either lopinavir or lopinavir SDNs were determined by multiplex 291 
suspension array. Lipopolysaccharide (100ng/mL) was used as a positive control. Data presented as 292 
mean ± SD, N=6. When compared to unstimulated cells *=P<0.05 & **=P<0.01 293 
 294 
Impact of lopinavir and lopinavir nanoparticles on phagocytosis by monocyte-derived 295 
macrophages 296 
Phagocytosis in MDM was assessed using fluorescent bioparticle uptake into MDM. MDM were 297 
treated with lopinavir or lopinavir SDNs for 24 hours prior to the assessment of bioparticle uptake. 298 
Cytochalasin was used as a known inhibitor of phagocytosis and bioparticle uptake was shown to be 299 
3.5-fold lower (P=0.035) in MDM treated with cytochalasin (figure 5). Treatment of MDM with either 300 
lopinavir or lopinavir SDNs did not significantly alter the uptake of bioparticles in MDM (figure 5). 301 
 302 
Figure 5. Impact of lopinavir and lopinavir solid drug nanoparticles on the uptake of fluorescent 303 
bioparticles in monocyte derived macrophages as a measure of phagocytosis. Bioparticle uptake 304 
was measured by fluorescence spectroscopy 24 hours post incubation with lopinavir of lopinavir 305 
SDNs. Cytochalasin was used as a positive control. Data presented as mean ± SD, N=6.  306 
 307 
  308 
DISCUSSION 309 
Determining the interaction of nanomaterials with cells of the immune system is key to 310 
understanding potentially limiting safety issues. This is particularly relevant in conditions where the 311 
primary target for the active pharmaceutical ingredient is within cells of the immune system, such as 312 
in the treatment of HIV. This is the first study to investigate the impact of SDNs on the function of 313 
primary human T cells and monocyte-derived macrophages, despite over 25 SDN-based medicines 314 
being approved for use in humans. This work formed part of a putative safety assessment of LPV 315 
SDNs, driven by the ambition to explore the potential for improved accumulation within these cell 316 
types (to supplement potential benefits in terms of pharmacokinetics). 317 
Using an emulsion-templated freeze-drying approach [17, 18, 23], lopinavir SDNs were produced 318 
with reproducible physico-chemical characteristics and previously shown to be bioequivalent to a 319 
conventional preclinical preparation of lopinavir in a rodent model. Importantly, the lopinavir SDNs 320 
are capable of dispersion in water thereby overcoming the issues of current paediatric dosing 321 
formats, which contain a high content of organic solvent [18].  The presence of endotoxin in 322 
nanoparticle samples can result in potentially false positive results in studies of immunogenicity [24] 323 
and it is therefore important to determine the concentration of endotoxin in nanomaterial 324 
preparations before embarking on such studies. The concentration of endotoxin in both the aqueous 325 
lopinavir solution and lopinavir SDNs was very low and unlikely to interfere with immunological 326 
assays. Additionally, using samples spiked with a known amount of endotoxin, lopinavir aqueous 327 
solution and the lopinavir SDNs do not interfere with recovery of endotoxin. Indeed, the results from 328 
endotoxin spiked samples were well within the 50-200% recovery acceptable by the USA and EU 329 
pharmacopoeia.  330 
Previous reports within the literature have shown that nanoparticles can stimulate T cells and, 331 
depending on their physico-chemical properties, can result in differential activation of either Th1 or 332 
Th2 profiles. The potential for lopinavir and/or lopinavir SDNs to stimulate T cells was investigated 333 
and neither aberrantly stimulated T cells to produce Th1 or Th2 cytokines. However, when cells were 334 
pre-treated with lopinavir or lopinavir SDNs for 24 hours prior to control stimulation the secretion of 335 
IL-2 was significantly higher than when cells were stimulated with beads and material 336 
simultaneously. This suggests an enhancement of the stimulatory effects of the beads by the 337 
lopinavir, which is independent of SDN formation. It has been shown previously that lopinavir can 338 
increase the amount of reactive oxygen species in a number of cell types [25, 26]. Reactive oxygen 339 
species are well known as mediators of inflammation and it is possible that this enhanced 340 
stimulation is a result of lopinavir eliciting endoplasmic reticulum stress. Importantly, lopinavir SDNs 341 
did not differ significantly in their impact on stimulation from that of a lopinavir solution. 342 
Additionally, the expression of cell surface receptors associated with T-cell activation [27-30] was 343 
monitored in response to incubation with the lopinavir SDNs or a lopinavir aqueous solution. No 344 
differences in expression between SDNs and aqueous solution and no differences in the response to 345 
anti-CD3/antiCD28 beads were observed in either CD4+ or CD8+ T cells. Finally, no difference in 346 
proliferation of PBMC from healthy volunteers were observed between SDNs and aqueous solution, 347 
and neither interfered with proliferation in response to the known mitogen, PHA. 348 
Secretion of cytokines from macrophages in response to treatment with lopinavir or lopinavir SDNs 349 
was also assessed. LPS treatment resulted in significantly higher secretion of IL- ?ɴ ? />-6, IL-8 and 350 
TNFɲ from MDM, which is in line with previously published observations [31, 32]. Aqueous lopinavir 351 
treatment resulted in significantly higher IL- ?ɴ ĂŶĚ dE&ɲ secretion from MDM compared to 352 
unstimulated cells. This is also in agreement with previous reports that have shown lopinavir induces 353 
the secretion of IL-6 and TNFɲ in rat peritoneal macrophages [6]. It is possible that subtle differences 354 
between rodent and human intracellular signalling can explain why IL-6 secretion was not 355 
significantly different in the current study. However, further work may be required to confirm this 356 
and clarify the underlying mechanisms. Lopinavir SDNs did not significantly alter cytokine secretion 357 
from MDM compared to untreated cells. This is particularly interesting and further work is required 358 
to elucidate why this difference between solution and SDNs was evident. However, the observation 359 
potentially represents an attractive feature of this particular type of nanoparticle as it appears to 360 
have reduced a possibly unintentional effect of lopinavir. The possible consequences of this 361 
differential induction of IL- ?ɴĂŶĚdE&ɲ now warrant further investigation to determine additional 362 
effects. The impact of IL- ?ɴĂŶĚdE&ɲ in HIV infection are still under debate; elevated concentrations 363 
of these proinflammatory cytokines have linked to aging of the immune system [33] and therefore 364 
lower levels of these cytokines induced by lopinavir SDN may ameliorate the effects of standard 365 
formulations of lopinavir on the aging of the immune system. IL- ?ɴĂŶĚdE&ɲ have been shown to 366 
play a major role in neuronal death (and subsequent associations with HIV associated dementia) as 367 
well as increasing the permeability of the blood-brain barrier to allow HIV infected monocytes to 368 
enter the brain [34]. Lower levels of these cytokines induced by lopinavir SDN may also prevent 369 
subsequent side effects but these issues need to be assessed in clinical trials. Finally, the impact of 370 
lopinavir and lopinavir SDNs on phagocytosis in MDM was assessed. Previous reports in the 371 
literature have shown the primary route of uptake into professional antigen presenting cells to be 372 
phagocytosis [35, 36]. Given the possibility of interference with this vital mechanism in MDM the 373 
impact of lopinavir and lopinavir SDNs on the uptake of fluorescent bioparticles was assessed. 374 
Cytochalasin was used as a known inhibitor of phagocytosis and a significantly lower uptake of 375 
bioparticles was observed in treated MDM. Lopinavir and lopinavir SDNs again did not significantly 376 
affect the uptake of bioparticles into MDM suggesting no interference with this mechanism.  377 
Our putative immunological safety assessment uncovered no obvious issues, but additional 378 
investigation in other cells of the immune system is now warranted to confirm biocompatibility. The 379 
formation of lopinavir SDNs may have the potential to mitigate unwanted effects whilst improving 380 
the bioavailability of lopinavir. This lopinavir SDN formulation, given its bioequivalence and 381 
comparative safety to conventional lopinavir preparations, is a viable option for pharmaceutical 382 
scalable manufacture, has been manufactured to GMP standards, and is currently undergoing 383 
assessment in a healthy volunteer clinical trial (EudraCT number 2013-004913-41). Given that SDNs 384 
are being investigated as intravenous, intramuscular and subcutaneous administration formats, 385 
these data bode well for the direct administration of such materials. However, similar work with 386 
SDNs composed of other drug molecules is required to confirm the appropriateness of generalising 387 
these observations across this class of nanomaterial. 388 
  389 
Future perspective 390 
Assessing the biocompatibility of novel, engineered, nanomaterials is an ongoing challenge in the 391 
field of nanomedicine. A number of points must be considered including, but not limited to; 392 
standardisations of the techniques used in biocompatibility assessment to more easily compare 393 
results between researchers, a more complete analysis of the healthy volunteers samples that are 394 
used in these studies to understand potential inter-individual variability and comprehensive physical 395 
characterisation of the materials under investigation to clearly identify relationships between 396 
nanoparticle characteristics and biological effect. 397 
 398 
Executive Summary 399 
Background 400 
x Solid drug nanoparticles of Lopinavir have previously been demonstrated to have a number 401 
of pharmacological benefits for use in paediatric patients by mitigating the need for organic 402 
solvents and/or augmenting bioavailability.  403 
x The formulation described in this paper is currently undergoing assessment in human 404 
healthy volunteers.  405 
x The interaction of nanomaterials with immunological systems is a developing field of 406 
research but, to date; solid drug nanoparticles have not been extensively studied. Therefore 407 
we assessed the impact of these nanoparticles on T cell and macrophage function 408 
Results 409 
x Endotoxin was present in the studied formulations however; it was present at very low 410 
levels unlikely to induce an immunological response.  411 
x Solid drug nanoparticles did not induce the same immunogenic response as conventional 412 
lopinavir. 413 
x No other interactions with T cells or monocyte-derived macrophages were observed. In 414 
these ex vivo analyses, lopinavir SDNs were demonstrated to be immunologically inert on 415 
exposure to human T cells and monocyte-derived macrophages.  416 
Conclusion 417 
x Lopinavir was shown to induce the secretion of proinflammatory cytokines however further 418 
clarification of the impact of this on disease progression, and treatment, in HIV patients 419 
requires further clarification. 420 
x The Lopinavir solid drug nanoparticles did not interfere with normal responses of T cells and 421 
macrophages within this study. This suggests that their accumulation within these cells 422 
should not raise any particular issues. 423 
 424 
 425 
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 454 
Supplementary figure 1. Representative DLS traces of Lopinavir solid drug nanoparticles 455 
dispersed in water. Samples dispersed at 1 mgmL
-1
 in water at 25
o
C. 456 
 457 
 458 
 459 
 460 
 461 
 462 
 463 
 464 
 465 
 466 
 467 
Supplementary figure 2. Measurement of (a) z-average and (b) zeta potential of lopinavir 468 
solid drug nanoparticles over a range of pH. Samples dispersed at 1 mgmL
-1
 in water at 25
o
C. 469 
 470 
 471 
 472 
 473 
 474 
Supplementary figure 3. Stability of lopinavir solid drug nanoparticles as determined by 475 
measurement of (a) z-average, (b) polydispersity index and (c) zeta potential over a period 476 
of 35 hours. After addition of water to the emulsion-templated monolith and subsequent 477 
dynamic light scattering measurements. Samples dispersed at 1 mgmL
-1
 in water at 25
o
C. 478 
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